Repeated Sigma-1 Receptor Antagonist MR309 Administration Modulates Central Neuropathic Pain Development After Spinal Cord Injury in Mice

• Autori principali: Sílvia Castany (Autore), Xavier Codony (Autore), Daniel Zamanillo (Autore), Manuel Merlos (Autore), Enrique Verdú (Autore), Pere Boadas-Vaello (Autore)
• Natura: Libro
• Pubblicazione: Frontiers Media S.A., 2019-03-01T00:00:00Z.
• Soggetti: article
• Accesso online: Connect to this object online.

Up to two-thirds of patients affected by spinal cord injury (SCI) develop central neuropathic pain (CNP), which has a high impact on their quality of life. Most of the patients are largely refractory to current treatments, and new pharmacological strategies are needed. Recently, it has been shown th...